Zymeworks Inc.
A Vancouver-based biopharmaceutical company that engineers antibody-based cancer therapies. Its Azymetric platform builds bispecific antibodies that can latch onto two targets at once, while its ZymeLink technology attaches chemotherapy drugs to antibodies to deliver them straight to tumors. Founded in 2003, the company's lead drug, zanidatamab, targets HER2-positive cancers.
Bought 2.16M
Bought 8.15M
Bought 30.5K
Granted 415.0K
Granted 440.3K · Sold 213.5K
Granted 17.7K · Sold 6.1K
Granted 109.2K · Sold 60.7K
Granted 57.7K · Sold 31.0K
Granted 5.2K · Sold 3.0K
Granted 5.9K · Sold 2.5K
Granted 13.6K · Sold 7.8K
Granted 459
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Nodelman Oleg +1 co-filerDirector, 10% owner · 22 transactions | — | 22.97Mas of Jun 2025 | — | 2.16M | — |
| EcoR1 Capital, LLCDirector, 10% owner · 25 transactions | — | 15.72Mas of Jan 2025 | — | 8.15M | — |
| Green Jeremy +1 co-filer10% owner · 1 transaction | — | 12.12Mas of Oct 2022 | — | 30.5K | — |
| Ciongoli Gregory AustinDirector · 1 transaction | — | 572.0Kas of Aug 2025 | 415.0K | — | — |
| Galbraith KennethChair & CEO, Director · 15 transactions | — | 226.8K | 440.3K | — | 213.5K |
| Hollywood MarkEVP & Chief Operating Officer · 2 transactions | — | 121.4K | 17.7K | — | 6.1K |
| Moore Paul AndrewChief Scientific Officer · 13 transactions | — | 48.5K | 109.2K | — | 60.7K |
| Smith Jeffrey T LEVP & Chief Medical Officer · 6 transactions | — | 26.7K | 57.7K | — | 31.0K |
| Klompas Neil APresident & COO · 3 transactions | — | 17.7Kas of Mar 2023 | 5.2K | — | 3.0K |
| Josephson NeilChief Medical Officer · 2 transactions | — | 14.4Kas of Nov 2022 | 5.9K | — | 2.5K |
| Astle ChristopherSVP & Chief Financial Officer · 7 transactions | — | 6.5Kas of Jan 2024 | 13.6K | — | 7.8K |
| Patterson Leone DEVP, Chief Bus & Fin Officer · 1 transaction | — | 459 | 459 | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: +10.02M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.